Vilanti 100 Cozycap

Indications

• Long-term, once-daily maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
• Once-daily treatment of asthma in patients aged 18 years and older.
• Important limitation of use: Not indicated for relief of acute bronchospasm.

Composition

• 25/100 inhalation capsule: Vilanterol 25 mcg (as Vilanterol Trifenatate INN) & Fluticasone Furoate INN 100 mcg.
• 25/200 inhalation capsule: Vilanterol 25 mcg (as Vilanterol Trifenatate INN) & Fluticasone Furoate INN 200 mcg.

Description

• Vilanterol Trifenatate: Selective, long-acting beta-2 agonist.
• Fluticasone Furoate: Corticosteroid with mainly glucocorticoid activity, exerting a topical effect on the lungs without systemic effects at usual doses.

Pharmacology

• Combination of vilanterol and fluticasone furoate.
• Vilanterol: Stimulates intracellular adenyl cyclase, leading to bronchial smooth muscle relaxation.
• Fluticasone furoate: Wide-ranging anti-inflammatory actions on various cell types and mediators involved in inflammation.

Dosage & Administration

• Oral inhalation only, not for swallowing.
• 1 inhalation of 25/100 mcg once daily for COPD maintenance treatment.
• 1 inhalation of 25/100 mcg or 25/200 mcg once daily for asthma treatment.

Interaction

• Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole): Use with caution.
• Monoamine oxidase inhibitors and tricyclic antidepressants: Extreme caution advised.
• Beta-blockers: Caution recommended.
• Diuretics: Use with caution, monitor for electrocardiographic changes and hypokalemia.

Contraindications

• Primary treatment of status asthmaticus or acute episodes of COPD or asthma.
• Severe hypersensitivity to milk proteins or any ingredients.

Side Effects

• Nasopharyngitis, oral candidiasis, headache, upper respiratory tract infection, bronchitis, sinusitis, cough, among others.

Use in Special Populations

• Not indicated for use in children and adolescents.
• Monitor patients with hepatic impairment for systemic corticosteroid effects.

Overdose Effects

• No clinical trial data available.

Therapeutic Class

• Respiratory corticosteroids.

Storage Conditions

• Store in a cool, dry place away from sunlight and heat.
• Keep out of reach of children.

Precautions & Warnings

• Increased risk of serious asthma-related events with LABA monotherapy.
• Do not initiate during acute exacerbations.
• Risk of pneumonia in COPD patients.
• Increased risk of infections, impaired adrenal function, paradoxical bronchospasm, and cardiovascular effects.
• Use with caution in patients with various disorders and monitor accordingly.